Changes in the treatment of Enterococcus faecalis infective endocarditis in Spain in the last 15 years: From ampicillin plus gentamicin to ampicillin plus ceftriaxone

Clinical Microbiology and Infection

Volumn 20, Issue 12, 2014, Pages O1075-O1083

  Pericas, J M ^a   Cervera, C ^a   del Rio, A ^a   Moreno, A ^a   Garcia de la Maria, C ^a   Castaneda X ^a   Armero, Y ^a   Gatell, J M ^a   Miro, J M ^a   Almela, M ^a   Marco, F ^a   Falces, C ^a   Ninot, S ^a   Mestres, C A ^a   Soy, D ^a   Miro, Jose M ^a   Pericas, Juan M ^a   Castañeda, Ximena ^a   Cervera, Carlos ^a   Moreno, Asuncion ^a   Gatell, Jose M ^a   de la Mária, Cristina Garcia ^a   Armero, Yolanda ^a   Marco, Francesc ^a   Almela, Manel ^a   Vila, Jordi ^a   Mestres, Carlos A ^a   Paré, Juan C ^a   Falces, Carlos ^a   Cartañá, Ramón ^a   Ninot, Salvador ^a   Azqueta, Manel ^a   Sitges, Marta ^a   Heras, Magda ^a   Pomar, José L ^a   Quintana, Eduard ^a   Pereda, Daniel ^a   Castellá, Manel ^a   Fita, Guillermina ^a   Rovira, Irene ^a   Ramírez, Jose ^a   Ribalta, Teresa ^a   Brunet, Merce ^a   Soy, Dolors ^a   Llopis, Jaume ^a   more..

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Enterococcus faecalis; Ampicillin plus ceftriaxone; Antimicrobial treatment; High level aminoglycoside resistance; Infective endocarditis; Outcomes

Indexed keywords

ENTEROCOCCUS FAECALIS;

AMPICILLIN; ANTIINFECTIVE AGENT; CEFTRIAXONE; GENTAMICIN;

AGED; ANTIBIOTIC RESISTANCE; CHEMICALLY INDUCED; COHORT ANALYSIS; DRUG COMBINATION; DRUG EFFECTS; ENDOCARDITIS; ENTEROCOCCUS FAECALIS; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMAN; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY; RENAL INSUFFICIENCY; SPAIN; SURVIVAL; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMPICILLIN; ANTI-BACTERIAL AGENTS; CEFTRIAXONE; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; ENDOCARDITIS; ENTEROCOCCUS FAECALIS; FEMALE; GENTAMICINS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; SPAIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84908324298     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12756     Document Type: Article

References (36)

1. Murdoch DR, Corey GR, Hoen B et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 2009; 169: 463-473.
2. Durante-Mangoni E, Bradley S, Selton-Suty C et al. Current features of infective endocarditis in elderly patients: results of the International Collaboration on Endocarditis Prospective Cohort Study. Arch Intern Med 2008; 168: 2095-2103.
3. McDonald JR, Olaison L, Anderson DJ et al. Enterococcal endocarditis: 107 cases from the international collaboration on endocarditis merged database. Am J Med 2005; 118: 759-766.
4. Martinez-Marcos FJ, Lomas-Cabezas JM, Hidalgo-Tenorio C et al. [Enterococcal endocarditis: a multicenter study of 76 cases]. Enferm Infecc Microbiol Clin 2009; 27: 571-579.
5. Benito N, Miro JM, de Lazzari E et al. Health care-associated native valve endocarditis: importance of non-nosocomial acquisition. Ann Intern Med 2009; 150: 586-594.
6. Fernandez Guerrero ML, Goyenechea A, Verdejo C et al. Enterococcal endocarditis on native and prosthetic valves: a review of clinical and prognostic factors with emphasis on hospital-acquired infections as a major determinant of outcome. Medicine (Baltimore) 2007; 86: 363-377.
7. Chirouze C, Athan E, Alla F et al. Enterococcal endocarditis in the beginning of the 21st century: analysis from the International Collaboration on Endocarditis-Prospective Cohort Study. Clin Microbiol Infect. 2013; 19: 1140-1147.
8. Anderson DJ, Olaison L, McDonald JR et al. Enterococcal prosthetic valve infective endocarditis: report of 45 episodes from the International Collaboration on Endocarditis-merged database. Eur J Clin Microbiol Infect Dis 2005; 24: 665-670.
9. Cabell CH, Jollis JG, Peterson GE et al. Changing patient characteristics and the effect on mortality in endocarditis. Arch Intern Med 2002; 162: 90-94.
10. Munita JM, Arias CA, Murray BE. Enterococcal endocarditis: can we win the war? Curr Infect Dis Rep 2012; 14: 339-349.
11. Jawetz E, Gunnison JB, Coleman VR. The combined action of penicillin with streptomycin or chloromycetin on enterococci in vitro. Science 1950; 111: 254-256.
12. Baddour LM, Wilson WR, Bayer AS et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111: e394-e434.
13. Olaison L, Schadewitz K. Enterococcal endocarditis in Sweden, 1995-1999: can shorter therapy with aminoglycosides be used? Clin Infect Dis 2002; 34: 159-166.
14. Gavalda J, Len O, Miro JM et al. Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med 2007; 146: 574-579.
15. Habib G, Hoen B, Tornos P et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Eur Heart J 2009; 30: 2369-2413.
16. Li JS, Sexton DJ, Mick N et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000; 30: 633-638.
17. Wilson WR, Karchmer AW, Dajani AS et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association. JAMA 1995; 274: 1706-1713.
18. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
19. Fliser D, Laville M, Covic A et al. A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant 2012; 27: 4263-4272.
20. Lerner AM, Reyes MP, Cone LA et al. Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin. Lancet 1983; 1: 1123-1126.
21. Donowitz GR, Mandell GL. Drug therapy. Beta-lactam antibiotics (2). N Engl J Med 1988; 318: 490-500.
22. Europe C. EARSS Annual Report 2007. Consulted at: http://www.ecdc.europa.eu/en/activities/surveillance/earsnet/documents/2007_earss_annual_report.pdf. 2007.
23. Kuch A, Willems RJ, Werner G et al. Insight into antimicrobial susceptibility and population structure of contemporary human Enterococcus faecalis isolates from Europe. J Antimicrob Chemother 2012; 67: 551-558.
24. Eliopoulos GM. Aminoglycoside resistant enterococcal endocarditis. Infect Dis Clin North Am 1993; 7: 117-133.
25. Cervera C, Almela M, Martinez-Martinez JA et al. Risk factors and management of Gram-positive bacteraemia. Int J Antimicrob Agents 2009; 34: S26-S30.
26. Antalek MD, Mylotte JM, Lesse AJ et al. Clinical and molecular epidemiology of Enterococcus faecalis bacteremia, with special reference to strains with high-level resistance to gentamicin. Clin Infect Dis 1995; 20: 103-109.
27. Zarrilli R, Tripodi MF, Di Popolo A et al. Molecular epidemiology of high-level aminoglycoside-resistant enterococci isolated from patients in a university hospital in southern Italy. J Antimicrob Chemother 2005; 56: 827-835.
28. Araoka H, Kimura M, Yoneyama A. A surveillance of high-level gentamicin-resistant enterococcal bacteremia. J Infect Chemother 2011; 17: 433-434.
29. Wilson WR, Wilkowske CJ, Wright AJ et al. Treatment of streptomycin-susceptible and streptomycin-resistant enterococcal endocarditis. Ann Intern Med 1984; 100: 816-823.
30. McBride SM, Fischetti VA, Leblanc DJ et al. Genetic diversity among Enterococcus faecalis. PLoS One 2007; 2: e-582.
31. Mainardi JL, Gutmann L, Acar JF et al. Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis. Antimicrob Agents Chemother 1995; 39: 1984-1987.
32. Gavalda J, Onrubia PL, Gomez MT et al. Efficacy of ampicillin combined with ceftriaxone and gentamicin in the treatment of experimental endocarditis due to Enterococcus faecalis with no high-level resistance to aminoglycosides. J Antimicrob Chemother 2003; 52: 514-517.
33. Gavalda J, Torres C, Tenorio C et al. Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides. Antimicrob Agents Chemother 1999; 43: 639-646.
34. Fernandez-Hidalgo N, Almirante B, Gavalda J et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating Enterococcus faecalis infective endocarditis. Clin Infect Dis 2013; 56: 1261-1268.
35. Dahl A, Rasmussen RV, Bundgaard H et al. Enterococcus Faecalis infective endocarditis: a pilot study on the relationship between duration of gentamicin treatment and outcome. Circulation 2013; 127: 1810-1877.
36. Miro JM, Pericas JM, Del Rio A. A new era for treating Enterococcus Faecalis endocarditis: ampicillin plus short-course gentamicin or ampicillin plus ceftriaxone: that is the question! Circulation 2013; 127: 1763-1766.